Program Highlights

Get a sneak peek into the topics being discussed in the following sessions from the speakers who will be presenting:

​Session 1b
NAFLD the Big Picture 
​Thursday, 1 June 2017
​Pierre Bedossa (France)

Histological Definition of NAFLD 

NAFLD is the combination of several different elementary features of variable intensity and of different prognostic values including steatosis, fibrosis and activity.

The dichotomous classification distinguishing NAFL (steatosis) from NASH is an oversimplification which is no more relevant in clinical practice. New proposals have been formulated and will be reviewed.

​Session 3
Recognizing NAFLD in Your Practice
​Thursday, 1 June 2017
Quentin M. Anstee (UK) 

Why Should You Care about NAFLD? 

A review of disease epidemiology and natural history highlighting the prevalence and currently un met clinical needs. 

​Session 4
NASH and Cardiovascular Disease
​Friday, 2 June 2017
J.A. (Ton) Lisman (Netherlands)

Coagulation and NAFLD

NAFLD is associated with a risk for thrombosis which may involve NAFLD-induced prothrombotic changes in the hemostatic system. I will present recent data that argue against NAFLD-induced hypercoagulability, suggesting other factors are involved in NAFLD-associated thrombosis.

​Session 5
Diabetes and NAFLD 
​Friday, 2 June 2017
Bart Staels (France) 

Entero-hepatic Lipid-signaling in the Metabolic Syndrome and NAFLD

The liver and intestine reciprocally cross-talk through lipid-signaling molecules to activate transcriptional networks and signaling cascades controlling the expression and activity of genes involved in lipid and carbohydrate metabolism, energy expenditure, inflammation and fibrosis. This inter-organ signaling including an interplay with the gut microbiota impacts on pathophysiological conditions such as obesity, type 2 diabetes, CVD and non-alcoholic steatohepatitis and hence has potential therapeutic applications.

​​Session 5
Diabetes and NAFLD 
​​Friday, 2 June 2017
Jerry L. Nadler (USA) 

Diabetes and NAFLD - is it One Disease Two Target Organs

There is a worldwide epidemic of Type 2 diabetes mellitus (T2DM) that is associated with insulin resistance and other features of the metabolic syndrome. A large number of patients with nonalcoholic fatty liver disease (NAFLD) move to inflammatory nonalcoholic steatohepatitis (NASH). A high incidence of T2DM patients with NASH develop additional complications such as liver cirrhosis, hepatocellular carcinoma and cardiovascular disease. 

The talk will focus on this epidemic, help clarify the reasons for accelerated NASH risk in diabetes and discuss new aspects of therapy today and in the future.

​Session 8
The GREAT DEBATE - Is it Time to Drop Liver Histology as the Anchor for Assessment of NAFLD Evolution? 
Saturday, 3 June 2017
​Pierre Bedossa (France)

Liver biopsy is the only approach to assess directly liver damages. Since NASH is defined by histological criteria, biopsy is needed if diagnosis and evaluation of severity are required, at baseline or in the follow-up.

Histology of NAFLD is based on association of different patterns (fibrosis, inflammation, ballooning, steatosis…). Only liver biopsy can accurately assess and quantitate all these features at once. 

​Session 10
What to do When You Find the Disease – Behavior Modification 
​Saturday, 3 June 2017
Shira Zelber-Sagi (Israel)

Managing the Low Risk Patient…Providing Practical Advice Regarding Diet and Exercise – Nutritionist Perspective

Weight reduction is the most established treatment for NAFLD and NASH. In addition, recent studies emphasized the independent therapeutic effect of replacing unhealthy Western dietary pattern, typical to NAFLD patients, with a healthy dietary pattern like the Mediterranean diet. The talk will provide a practical, evidence-based, effective approach for the lifestyle treatment of NAFLD patients. 

​Session 10
What to do When You Find the Disease – Behavior Modification 
​​Saturday, 3 June 2017
Ramon Bataller (USA)
Alcohol Consumption in the Obese Diabetic Subject- How Much or How Little

There is evidence that heavy alcohol intake accelerates the progression of liver disease in patients with metabolic syndrome (i.e. obesity and type 2 diabetes). While daily intake of a cup of wine could have beneficial effects in the general population, consumption of 3 or more drinks in obese patients promotes the development of cirrhosis and hepatocellular carcinoma.

​Session 11
Therapeutic Landscape for NASH
​Saturday, 3 June 2017
Quentin M. Anstee (UK) 
Targets Under Evaluation in Early Phase Trials

A review of novel therapeutic agents and their targets that are currently under evaluation in clinical trials. 

Keep Me Updated

​​​ ​​​​​ ​​​​​ ​​​​​